Literature DB >> 2201441

Epidemiology and immunovirology of human T-cell leukemia/lymphoma virus type I-associated adult T-cell leukemia and chronic myelopathies as seen in France.

A Gessain1, O Gout, F Saal, M T Daniel, B Rio, G Flandrin, F Sigaux, O Lyon-Caen, J Periès, G de-Thé.   

Abstract

Seventeen patients with adult T-cell leukemia (ATL) and 21 with tropical spastic paraparesis/human T-cell leukemia/lymphoma virus type I (HTLV-I)-associated myelopathy (TSP/HAM) were observed during a 3-yr survey (1986-1988) in some hospitals in Paris, France. Most of them were black, originating from high-HTLV-I-endemic areas (West Indies or Africa), but two cases of TSP/HAM occurred in French Caucasians. In one case, the patient acquired the virus from a transfusion during a cardiac transplantation. Most of the ATL cases were diagnosed as acute leukemia or lymphoma, with a proliferation of CD2+, CD3+, CD4+, CD8-, DR+, and CD25+ lymphoid cells. Only three cases were diagnosed as a smoldering ATL. All of the TSP/HAM cases exhibited a spastic paraparesis with a chronic and slow evolution and high HTLV-I antibody titers in serum and cerebrospinal fluid, with a high HTLV-I antibody index and specific HTLV-I immunoglobulin = oligoclonal bands. In TSP/HAM, a high percentage of DR-expressing cells (15 to 40%) was found, with a slightly elevated CD4/CD8 ratio. This was associated with the presence of 1 to 10% abnormally shaped nuclei in lymphoid cells and a polyclonal integration of HTLV-I proviruses in these peripheral blood mononuclear cells. On the contrary, a clonal integration was always found in the ATL malignant cells (leukemic, lymph node, and cutaneous infiltrate). Long-term interleukin 2-dependent T-cell lines (CD2+, CD3+, CD4+, and WT31+) with activated T-cell markers (CD25+ and DR+) producing HTLV-I were established from ATL and TSP/HAM peripheral blood mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201441

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  In vivo genomic variability of human T-cell leukemia virus type I depends more upon geography than upon pathologies.

Authors:  F Komurian; F Pelloquin; G de Thé
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations.

Authors:  A Gessain; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Chromosomal localization of HTLV-1 viral integration sites using in situ hybridization: detection of a novel IL2R fragment.

Authors:  M J Macera; P Szabo; R S Verma
Journal:  Mol Gen Genet       Date:  1992-09

5.  Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis.

Authors:  Simona Ozden; Madeleine Cochet; Jacqueline Mikol; Antonio Teixeira; Antoine Gessain; Claudine Pique
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

6.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

7.  Adult T-cell leukemia: a review of epidemiological evidence.

Authors:  Masako Iwanaga; Toshiki Watanabe; Kazunari Yamaguchi
Journal:  Front Microbiol       Date:  2012-09-10       Impact factor: 5.640

8.  Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil.

Authors:  Pedro Dantas Oliveira; Ítala Gomes; Victor Hugo Gomes Souza; Ernesto Cunha Pires; Glória Bomfim Arruda; Achiléa Bittencourt
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.